E-cigarette Switching Older Adults
Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jul 30, 2024
Trial Information
Current as of September 10, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Volunteers will be patients diagnosed with opioid use disorder (OUD) who have been in medication-based treatment (methadone or buprenorphine) at the University of Maryland Addiction Treatment Center (UMATC) at 1001 W Pratt Street for at least 3 months. The 3-month requirement will help to ensure that patients who enroll in this study have been stabilized on methadone and buprenorphine, which are first-line, evidence-based treatments for OUD.
All procedures associated with this study will be conducted at the UMATC. After completion of brief pre-screen questions to determine eligibility (i.e...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. 50 years or older; currently in treatment for opioid use disorder for at least 3 months
- • 2. currently use tobacco (\>100 cigarettes in lifetime and smoke every day or some days)
- • 3. xpired air CO \>8ppm
- • 4. does not regularly use e-cigarettes (regular use defined as use in the past month for 2 or more consecutive days)
- • 5. not pregnant or breastfeeding
- Exclusion Criteria:
- • 1. individuals trying to stop smoking or have a plan to quit smoking
- • 2. people age 49 or younger
- • 3. people who do not currently smoke tobacco
About University Of Maryland, Baltimore
The University of Maryland, Baltimore (UMB) is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, UMB leverages its extensive resources and expertise across various disciplines, including medicine, pharmacy, nursing, and social work, to contribute to groundbreaking discoveries and improve patient outcomes. Committed to ethical research practices and collaboration, UMB fosters an environment that promotes the translation of scientific knowledge into real-world applications, ultimately enhancing the well-being of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported